Abstract Background: The novel immune checkpoint human leukocyte antigen-G (HLA-G) is a promising candidate target for solid cancer immunotherapy. However, knowledge gaps on the clinical relevance of diverse HLA-G isoforms remain.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile